FDG-PET Imaging in Young Cystic Fibrosis Patients
Recruitment status was Recruiting
The purpose of this research is to determine how a person's lungs will uptake [18F]fluorodeoxyglucose (FDG), as measured with positron emission tomography (PET) scanning in young cystic fibrosis patients.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||FDG-PET Imaging in Young Cystic Fibrosis Patients|
|Study Start Date:||February 2009|
|Estimated Study Completion Date:||February 2012|
|Estimated Primary Completion Date:||February 2012 (Final data collection date for primary outcome measure)|
Procedure: [18F]FDG PET/CT
FDA-approved Investigational New Drug (IND) to use [18F]FDG in CF patients under the age of 18 years (PI: Robert Mach, MD, IND # 76079). Imaging data will be acquired with a Siemens Biograph 40PET/CT Tomograph. Research participants will be positioned supine in the scanner and a scout CT topograph obtained.
Other Name: [18F]FDG PET/CT
Our recent study in CF adults, supplemented by recent pre-clinical and clinical studies by our group suggests that FDG-PET imaging may be a valuable quantitative biomarker of lung inflammation. The proposed study would validate our earlier findings, but in a younger patient population. The implications of such a test could be highly significant for both the testing of promising new anti-inflammatory agents and for patient management decisions. To capitalize on this exciting opportunity, the critical next step is to show that we can identify a cohort of young CF patients with both stable lung function and normal (or near normal) FDG-PET imaging studies. Similar patients, then, would become the subjects for a future prospective cohort study to determine if FDG-PET imaging can in fact serve as a predictor of future changes in lung function.
|Contact: Thomas W Ferkol, MDfirstname.lastname@example.org|
|Contact: Mary G Boyle, RNemail@example.com|
|United States, Missouri|
|Washington University School of Medicine||Recruiting|
|St. Louis, Missouri, United States, 63110|
|Contact: Thomas W Ferkol, MD 314-454-2694 firstname.lastname@example.org|
|Contact: Mary G Boyle, RN, MSN 314-454-4609 email@example.com|
|Principal Investigator: Thomas W Ferkol, MD|
|Principal Investigator:||Thomas Ferkol, MD||Washington University School of Medicine|